TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
TherapeuticsMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.86−0.04 (-2.11%)
Close on Oct 19, 2026
- Market cap
- $21.66M
- P/E (TTM)
- –
- Dividend yield
- –
TherapeuticsMD, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-U.S. [Member] | $480.00K | $366.00K | $336.00K | $310.00K | $219.00K | $236.00K | $163.00K | $130.00K | $110.00K | – | – | – | 66.3% | +119.2% |
| United States | $244.00K | $527.00K | $448.00K | $642.00K | $174.00K | $431.00K | $384.00K | $104.00K | $203.00K | – | – | – | 33.7% | +40.2% |
From the segment and revenue-disaggregation notes of TherapeuticsMD's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.